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pathway, including RAF and MEK inhibitors.
The MEK inhibitor, trametinib, is FDA-approved for treatment of
unresectable or metastatic melanoma in patients with BRAF mutations.
There is also activity in KRAS mutations as both lead to activation of the
MAPK pathway. We report a case of treatment response to an MEK in-
hibitor in a patient with recurrent neuroendocrine carcinoma of the
cervix after molecular testing identiﬁed a KRAS mutation.
CaseA52-year-old Caucasian female experienced postmenopausal bleed-Introduction
Small cell neuroendocrine carcinoma (SCNEC) of the cervix is a rare
and aggressive formof cervical cancer. Comparedwith squamous cell or
adenocarcinoma of the cervix, SCNEC ismore likely to have lymph node
metastases, lymphovascular invasion, recurrence, and overall poorer
prognosis [1]. Neuroendocrine tumors can recur both locally and dis-
tantly within months after complete surgical resection with no residual
disease [2].
Molecular targeted therapy has been shown to have variable results
in non-gynecologic neuroendocrine tumors including small cell carcino-
ma of the lung, gastrointestinal stromal tumors (GIST) and pheochro-
mocytomas. C-kit is a growth factor receptor that contains tyrosine
kinase domains and is frequently mutated in GIST [3]. Imatinib is an
ATP analogue that has been shown to inhibit growth and proliferation
of GIST which frequently has c-kit mutations. Both partial and complete
responses have been observed in patients with GIST [3].
The RAS pathway is frequently targeted by mutations in human
cancers, which leads to deregulation of the pathway. One of the
most studied pathways is the RAF-mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)
MAPK cascade [4]. This pathway is involved in various key activities in-
cluding angiogenesis, apoptosis, and proliferation. Therapeutic agentsic Oncology and Reproductive
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. This is an open access article undering and was noted to have endometrial cells on her pap smear. She
underwent colposcopy, endometrial biopsy, and cervical biopsy as
part of the work-up. Final pathology of the cervical biopsy revealed
high-grade neuroendocrine carcinoma with mixed small cell and large
cell types. PET/CT was negative for metastatic disease. Clinical stage
was determined as IB1.
The primary treatment was robotic-assisted radical hysterectomy,
bilateral salpingoophorectomy, and bilateral pelvic lymph node
dissection. The margins of the tumor were negative and the lymph
nodes did not show any evidence of metastasis. Due to her high risk
histology, the patient underwent adjuvant chemo-radiation for a total
of 4500 cGy in 25 fractions concurrent withweekly cisplatin. After com-
pletion of radiation she received an additional 4 cycles of adjuvant cis-
platin and etoposide chemotherapy. At the conclusion of primary
treatment the patient was without evidence of disease both on physical
exam and CT scan of the chest, abdomen, and pelvis.
Approximately 4 months later, the patient was examined during a
surveillance visit and a 3 mm friable lesion was noted at the apex of
the right vaginal cuff. Biopsy conﬁrmed recurrence of the neuroendo-
crine carcinoma. PET/CT revealed disease limited to the vagina. Prior
to this, the tissue specimen from surgery was tested for molecular ge-
netics through an institutional testing program where a panel of 46
genes commonly associated with cancer is tested through next genera-
tion sequencing. The patientwas noted to have a KRASmutation detect-
ed in codon 12, exon 2 (GGT to GAT) of the KRAS gene that would
change the encoded amino acid fromGlycine to Aspartate (p.Gly12Asp).
Standardized nomenclature for this mutation is NM_033360.2 (KRAS):
c.35GNA p.G12D. No other genetic mutations were detected. She was
therefore started on an MEK inhibitor, trametinib off trial as there
were no MEK trials available at that time. The patient has undergonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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out evidence of disease as conﬁrmed by PET/CT.
The patient continues tomaintain an excellent quality of life and has
an Eastern Cooperative Oncology Group (ECOG) performance status of
0. Her only long-term treatment complication is chronic lymphedema
for which she receives massage therapy. She has been seen by ophthal-
mology secondary to visual disturbances after starting trametinib and
she was diagnosed with dry-eye and given hydrating eye drops.
Discussion
The current treatment of SCNEC of the cervix is extrapolated from
treatment for small cell carcinoma of the lung which involves a combi-
nation of surgery, chemotherapy, and/or radiation [5]. FIGO stage and
lymph node metastases have been proposed as signiﬁcant prognostic
factors in SCNEC of the cervix in one of the largest retrospective studies
to date [5]. Unfortunately, most patientswith SCNECwill develop recur-
rent disease. Recurrence of SCNEC of the cervix has been shown to occur
more frequently in women who did not receive initial systemic treat-
ment with chemotherapy [6]. Distant metastases are found more
commonly in the liver, bone, lung, and brain when compared to metas-
tases in squamous cell carcinoma of the cervix which more commonly
occur in the pelvis and lymph nodes.
Lee et al. compared rates of recurrence and survival between SCNEC
and squamous cell carcinoma of the cervix. They found that approxi-
mately 60% of patients with SCNEC recurred and the 5-year overall sur-
vival was 23.5% for SCNEC compared to 87.9% for the squamous cell
carcinoma group [7]. Given the extremely poor prognosis of SCNEC of
the cervix, treatment options for recurrent disease are of great impor-
tance. This is especially true since multi-modality treatment is being
used upfront in patients with early-stage SCNEC. After recurrence,
new treatment options are limited to second-line chemotherapy and
experimental treatments.
Targeted therapy for oncogenicmutations is an expandingﬁeldwith
promising new options for patients with refractory disease. KRASmuta-
tionswere found to have a prevalence of approximately 9% in a study by
Wright et al. that examined oncogenic mutations in squamous and
adenocarcinomas of the cervix [8]. KRAS mutations were only found in
those patients with adenocarcinoma, with no mutations present in
squamous cell carcinoma [8]. No change in survival was observed in
patients with KRAS mutation [8]. These ﬁndings, although not speciﬁc
for SCNEC of the cervix, demonstrate the potential of targeted therapy
for treatment of carcinoma of the cervix.
To our knowledge this is one of the ﬁrst reports of successful
treatment of recurrent SCNEC of the cervix using a MEK inhibitor.
Current literature using MEK inhibitors has been demonstrated formelanoma, non-small-cell lung cancer, breast, colon, and pancreatic
cancer.MEK inhibitors are approved treatment for advancedmelanoma,
but have not been shown to improve disease in breast, non-small-cell
lung, breast, colon, and pancreatic cancer [9]. At MD Anderson, we
have performed molecular testing in 20 women with small cell neuro-
endocrine cervical cancer and found 13 different mutations in 15
(75%) of these patients (5 tumor specimens had N1 mutation). The
two most common mutations seen were RAS (n = 4) and p53 (n =
4). (manuscript submitted for publication).
In this case, trametinib was used for recurrent SCNEC of the cervix in
a patient with a known KRAS mutation. The patient has been on
trametinib for 8 cycles now and is without evidence of disease. The
role of molecular testing to determine response to targeted therapies
is ongoing. This is particularly challenging in patients with rare tumors
where clinical trials are less available. This case highlights the potential
beneﬁts of molecular testing to determine treatment in a patient with a
rare but aggressive tumor, where conventional therapy has limitations.
Conﬂict of interest
There are no conﬂicts.
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